CoChat

Effects of atorvastatin on glucose homeostasis, postprandial triglyceride response and C‐reactive protein in subjects with impaired fasting glucose

Costa, A., Casamitjana, R., Casals, E., Álvarez, L., Morales, J., Masramón, X., Hernández, G., Gomis, R., Conget, I. · 2003 · Diabetic Medicine
Cited by 62

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Aims To investigate the effects of atorvastatin on glucose homeostasis, the basal and postprandial lipid profiles and the CRP levels (C reactive protein) in subjects with impaired fasting glucose (IFG). Methods Thirty‐three subjects (22 men and 11 women) were included in our study. All displayed an IFG (fasting plasma glucose between 6.1 and 7.0 mmol/l) on at least two occasions during the last 6 months prior the study. They were randomly assigned to receive either 40 mg atorvastatin/day (n= 16) or placebo (n= 17) over 16 weeks, in a double‐blind design. Before and after the end of the study all participants underwent on three consecutive days: a 75‐g oral glucose tolerance test, a frequent sampling intravenous glucose tolerance test with Minimal Model analysis and a meal tolerance test (glucose, insulin and triglycerides). CRP was measured before and after the treatment period. Results CRP decreased significantly in the atorvastatin‐treated group compared with the placebo group (percent change respect initial values; −42.3 %[−21.5 to − 63.1] and −9.6%[15.0 to −34.0], respectively, p < 0.01). Atorvastatin treatment did not produce any change in oral glucose tolerance categories or induce any change in glucose and insulin response in OGTT. The statin produced a trend towards a significant improvement in insulin sensitivity as expressed by a change in Si from baseline to the end of treatment. Atorvastatin reduced the postprandial response of triglycerides to the meal test compared with placebo (19–26 % across the meal test, p < 0.05) correlating with the amelioration observed in Si (−0.34, p < 0.05; percentage changes). Conclusion Our results suggest that the use of statins in subjects with IFG seems to include other potentially beneficial actions in addition to their cholesterol‐lowering effects.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1046/j.1464-5491.2003.00993.x

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 62

Metadata

Authors
Costa, A., Casamitjana, R., Casals, E., Álvarez, L., Morales, J., Masramón, X., Hernández, G., Gomis, R., & Conget, I.
Venue
Diabetic Medicine
Publisher
Wiley
Published
2003-08-19
Volume
20
Issue
9
Pages
743-745
ISSN
  • 0742-3071 (ISSN-L)
  • 1464-5491
OpenAlex
W1588310170
Cited by
62
References
3
FWCI
5.64
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.